Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments - Narrative (Details)

v3.19.1
Revenue Recognition and Contractual Adjustments - Narrative (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
segment
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Disaggregation of Revenue [Line Items]      
Number of operating segments | segment 2    
Increase in Pharma contract assets $ 300    
Pharma contract asset, increase (as a percent) 72.00%    
Increase in pharma contract liabilities $ 400    
Increase in pharma contract liabilities (as a percent) 14.00%    
Capitalized contract costs $ 1,076   $ 921
Pharma contract liability, revenue recognized 1,300 $ 900  
Amortization of contract commissions 200 $ 100  
Commissions      
Disaggregation of Revenue [Line Items]      
Capitalized contract costs $ 200    
Capitalized contract costs (as a percent) 17.00%